微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2020, Vol. 12 ›› Issue (4): 447-452.doi: 10.3969/j.issn.1674-5671.2020.04.15

• 临床研究 • 上一篇    下一篇

HJURP基因多态性与晚期肝细胞癌奥沙利铂为基础化疗疗效及不良反应的相关性

  

  1. 广西医科大学附属肿瘤医院化疗一科；广西医科大学第二附属医院肿瘤内科
  • 出版日期:2020-08-25 发布日期:2020-09-01
  • 通讯作者: 李永强。 E-mail：lyq702702@126.com
  • 基金资助:
    广西重点研发计划项目（桂科AB16380215）；广西自然科学基金项目（2017GXNSFAA198103；2017GXNSFBA198041； 2018GXNSFAA281129）；广西卫生和计划生育委员会自筹经费科研课题（Z20170452）

Association between HJURP gene polymorphism and the efficacy and adverse reactions of oxaliplatin-based chemotherapy for advanced hepatocellular carcinoma

  • Online:2020-08-25 Published:2020-09-01

PDF (PC)

231

赞

摘要： 目的 探讨Holliday交叉识别蛋白（holliday junction recognition protein，HJURP）基因多态性与含奥沙利铂方案一线治疗晚期肝细胞癌（hepatocellular carcinoma，HCC）疗效及不良反应的关系。方法 收集广西医科大学附属肿瘤医院的42例接受含奥沙利铂方案一线治疗的晚期肝细胞癌患者的临床资料及外周血样本，采用二代测序（next-generation sequencing，NGS）技术对HJURP基因7个位点进行分型，分析基因多态性与化疗疗效、预后及不良反应的关系。结果 42例患者的疾病控制率（DCR）为21.4%，HJURP基因多态性与DCR无关（P＞0.05）。全组患者中位无进展生存期（mPFS）为 1.5个月，中位总生存期（mOS）为4.4个月。携带rs3771333位点A/A型患者较A/C型患者的mOS更长（6.0个月 vs 1.3个月，P=0.016）。HJURP基因多态性与含奥沙利铂方案治疗的血液毒性、胃肠道毒性及神经毒性无关。结论 HJURP基因rs3771333位点多态性与含奥沙利铂方案治疗晚期HCC的预后有关，携带A/A基因型患者预后较好。

 

关键词: 肝细胞癌, HJURP, 单核苷酸多态性, 疗效, 不良反应

Abstract: Objective To investigate the association between holliday junction recognition protein（HJURP） gene polymorphism and oxaliplatin-based chemotherapy efficacy and adverse reactions in the first-line treatment for patients with advanced hepatocellular carcinoma（HCC）. Methods The clinical data and peripheral blood samples of 42 patients with advanced HCC received first-line treatment with oxaliplatin-based chemotherapy in Guangxi Medical University Cancer Hospital were collected. The next-generation sequencing（NGS） technology was used to classify the 7 loci of HJURP gene，and the relationship between gene polymorphism and chemotherapy efficacy，prognosis and adverse reactions was analyzed. Results Disease control rate（DCR）of 42 patients was 21.4%，and the polymorphism of HJURP gene was not related to DCR（P＞0.05）. The median progression-free survival（mPFS） was 1.5 months and the median overall survival（mOS） was 4.4 months. The mOS of patients carrying rs3771333 loci with A/A genotype was longer than those with A/C genotype（6.0 months vs 1.3 months，P=0.016）. The polymorphism of HJURP gene was not associated with hematotoxicity，gastrointestinal toxicity and neurotoxicity of oxaliplatin-based chemotherapy. Conclusions The rs3771333 polymor-phism of HJURP gene is associated with the prognosis of oxaliplatin-containing regimens in the treatment of advanced HCC，and patients with A/A genotype have better prognosis.

Key words: Hepatocellular carcinoma, HJURP, Single nucleotide polymorphism, Efficacy, Adverse reaction

中图分类号: 

  • R737.9